What is Congenica?
Congenica provides a sophisticated platform that empowers laboratories and clinicians to analyze complex sequencing data. Their software facilitates the interpretation of genetic variants, enabling the delivery of actionable genomic insights. The company's solutions are instrumental in diagnostic workflows for rare inherited diseases, cancer genomics, and the identification of pathogens in infectious disease testing. By bridging the gap between raw genomic data and clinical decision-making, Congenica is at the forefront of making genomic information accessible and impactful for patient care.
How much funding has Congenica raised?
Congenica has raised a total of $84.9M across 4 funding rounds:
Angel/Seed
$1.6M
Series A
$3.2M
Series B
$30.1M
Series C
$50M
Angel/Seed (2014): $1.6M with participation from Cambridge Innovation Capital
Series A (2015): $3.2M led by Cambridge Innovation Capital
Series B (2019): $30.1M supported by Cambridge Innovation Capital, Amadeus Capital Partners, Digital China Health Technologies Corporation, Future Planet Capital, Parkwalk Advisors, Helathlink Capital, and BGI Genomics
Series C (2020): $50M featuring Legal & General, Downing, Puhua Capital, IDO Investments, Tencent, Cambridge Innovation Capital, Parkwalk, and Xeraya
Key Investors in Congenica
Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies.
Legal & General
Legal & General Group plc is a prominent British financial services organisation and global investor, specializing in asset management and providing retirement, savings, and insurance products.
Tencent
Tencent Holdings Limited provides internet and mobile services, and online advertising services internationally, including online and mobile games and applications across various platforms.
What's next for Congenica?
The substantial enterprise-level funding Congenica has garnered, particularly the recent strategic investment, positions the company for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its interpretation platform, enhance its service offerings, and broaden its global reach. With a clear trajectory from its early-stage backing to its current scaling phase, Congenica is poised to solidify its leadership in the clinical genomics sector, driving innovation in diagnostic capabilities and contributing to improved patient outcomes worldwide.
See full Congenica company page
